Zyrtec OTC Switch: Pfizer Says Rx Status Necessary For “Best Use” Of Drug
This article was originally published in The Tan Sheet
Executive Summary
A forced OTC switch of Zyrtec would deprive consumers of the "health information component" doctors provide, which is needed for optimal care, Pfizer CEO Henry McKinnell said during the firm's April 24 annual meeting in Ann Arbor, Mich
You may also be interested in...
FDA Cautious On Forced Rx-To-OTC Switches
While FDA has concluded internally it has the authority to determine whether a drug should be Rx or OTC, the agency is being cautious about an official announcement of its position
Schering OTC Claritin Post-Approval Filings To Include Hypospadia Reports
Schering-Plough's post-approval commitments for OTC Claritin include submitting to FDA reported cases of the birth defect hypospadia following maternal ingestion of loratadine, the company said
Clarinex Clinical, Safety Characteristics Support OTC Use – WellPoint
The similar safety and efficacy profile of Schering-Plough's follow-on drug Clarinex (desloratadine) to other second-generation antihistamines makes it appropriate for OTC availability, WellPoint Health Networks asserts in an April 15 petition to FDA